Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Immune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Middha, Pooja, Thummalapalli, Rohit, Betti, Michael J., Yao, Lydia, Quandt, Zoe, Balaratnam, Karmugi, Bejan, Cosmin A., Cardenas, Eduardo, Falcon, Christina J., Faleck, David M., Gubens, Matthew A., Huntsman, Scott, Johnson, Douglas B., Kachuri, Linda, Khan, Khaleeq, Li, Min, Lovly, Christine M., Murray, Megan H., Patel, Devalben, Werking, Kristin, Xu, Yaomin, Zhan, Luna Jia, Balko, Justin M., Liu, Geoffrey, Aldrich, Melinda C., Schoenfeld, Adam J., Ziv, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246037/
https://www.ncbi.nlm.nih.gov/pubmed/37292751
http://dx.doi.org/10.1101/2023.05.15.23289680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246037/
https://www.ncbi.nlm.nih.gov/pubmed/37292751
http://dx.doi.org/10.1101/2023.05.15.23289680

Ejemplares similares